DelveInsight’s analysis indicates that the Atopic Dermatitis (AD) pipeline includes 100+ key companies actively developing over 120 treatment therapies aimed at addressing this chronic skin disorder.
Atopic Dermatitis Overview:
Atopic Dermatitis (AD), widely known as eczema, is a chronic inflammatory skin disease and the most common form of dermatitis. It typically manifests in early childhood but can occur at any age, often presenting a relapsing or persistent course. The condition is marked by dryness, itching, redness, and rashes, resulting from an interplay of genetic, immunological, and environmental factors.
Nearly 50% of individuals with moderate-to-severe AD also experience asthma, allergic rhinitis, or food allergies, highlighting its atopic nature. The primary symptom—intense itching—can lead to scratching, which triggers inflammation, thickening of the skin (lichenification), discoloration, and potential secondary infections.
The pathogenesis of AD involves skin barrier dysfunction, immune system dysregulation, IgE-mediated hypersensitivity, and environmental triggers. Mutations in the filaggrin gene compromise skin integrity by increasing water loss and altering pH, resulting in dehydration and heightened sensitivity. Additionally, an imbalance in Th2/Th1 cytokines drives abnormal immune responses and promotes IgE production. Histopathological features such as spongiosis allow inflammatory mediators to infiltrate the skin, while dendritic cells—including Langerhans, inflammatory dendritic epidermal, and plasmacytoid types—play key roles in initiating and sustaining disease activity.
Request for a detailed insights report on Atopic Dermatitis pipeline insights
DelveInsight’s “Atopic Dermatitis Pipeline Insight 2025” report offers an in-depth evaluation of the ongoing clinical research and development efforts, along with the emerging growth opportunities within the Atopic Dermatitis Therapeutics Market.
Key Takeaways from the Atopic Dermatitis Pipeline Report
-
DelveInsight’s Atopic Dermatitis Pipeline report highlights a dynamic and competitive landscape, with over 100 active companies developing more than 120 investigational therapies for the treatment of Atopic Dermatitis.
-
In September 2025, Amgen and Kyowa Kirin announced preliminary top-line results from the Phase 3 ASCEND extension study of rocatinlimab, a novel T-cell-rebalancing therapy targeting the OX40 receptor in adults/adolescents with moderate-to-severe AD.
-
In July 2024, the FDA approved a once-daily, steroid-free topical therapy for mild to moderate AD in patients aged 6 years and older. The treatment provides rapid itch relief and long-lasting control, suitable for use on all body areas, including sensitive skin regions.
-
In December 2024, another aryl hydrocarbon receptor agonist received FDA approval for treating AD in patients aged 2 years and older. Clinical studies demonstrated noticeable itch reduction within 24 hours and significant skin clearance by week 8, with many patients remaining symptom-free for approximately 80 days post-treatment.
-
Leading companies driving innovation in this field include Vanda Pharmaceuticals, TechnoDerma Medicines, Asana BioSciences, Artax Biopharma, Corvus Pharmaceuticals, Yuhan, BioVersys, Rubedo Life Sciences, Innocare Pharma, Apogee Therapeutics, Celldex Therapeutics, Aclaris Therapeutics, and Astria Therapeutics, among others.
-
Promising therapies in various stages of development include ICP-332, APG777, Barzolvolimab, ATI-2138, STAR-0310, and several additional candidates aimed at transforming the Atopic Dermatitis treatment landscape.
Atopic Dermatitis Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the key companies that are developing therapies in the Atopic Dermatitis Market.
-
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atopic Dermatitis treatment.
-
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Atopic Dermatitis market.
Download our free sample page report on Atopic Dermatitis pipeline insights
Atopic Dermatitis Emerging Drugs
ICP-332 – Innocare Pharma
ICP-332 is an advanced, highly selective TYK2 inhibitor being developed for the treatment of multiple T-cell–mediated autoimmune disorders, including atopic dermatitis (AD), vitiligo, and inflammatory bowel disease, representing significant therapeutic potential. TYK2, a member of the JAK kinase family, is a non-receptor tyrosine kinase essential to the JAK-STAT signaling pathway and is strongly associated with inflammatory disease mechanisms. Currently, ICP-332 is undergoing Phase III clinical evaluation for atopic dermatitis.
APG777 – Apogee Therapeutics
APG777 is a next-generation subcutaneous monoclonal antibody with an extended half-life, developed to target IL-13 for the treatment of atopic dermatitis (AD). In preclinical comparisons, it showed equal or superior potency to lebrikizumab in blocking IL-13 signaling. Phase 1 clinical results over a 12-month period demonstrated a half-life of 77 days, strong safety and pharmacodynamic outcomes, nearly complete inhibition of pSTAT6 for up to one year following a single dose, and long-lasting suppression of TARC levels. The drug is currently in Phase II clinical development for AD.
Atopic Dermatitis Companies
Around 100 or more major companies are actively engaged in developing therapies for Atopic Dermatitis, with InnoCare Pharma being among those that have drug candidates in the most advanced Phase III stage of development.
DelveInsight’s report covers around 75+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Atopic Dermatitis Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Atopic Dermatitis Therapies and Key Companies: Atopic Dermatitis Clinical Trials and advancements
Atopic Dermatitis Pipeline Therapeutic Assessment
• Atopic Dermatitis Assessment by Product Type
• Atopic Dermatitis By Stage
• Atopic Dermatitis Assessment by Route of Administration
• Atopic Dermatitis Assessment by Molecule Type
Download Atopic Dermatitis Sample report to know in detail about the Atopic Dermatitis treatment market @ Atopic Dermatitis Therapeutic Assessment
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
